ESR1 and breast cancer: This finding revealed that adaptation of HR+ breast cancer cells to estrogen deprivation can lead to tumor dependency on PI3K signaling [42], and both preclinical and clinical data support the efficacy of combination therapies targeting ER and PI3K/Akt pathway to overcome acquired endocrine resistance [41,42].